A further network pharmacological analysis showed that NOS2 was indeed a great, promising target for formononetin and calycosin (FMN/CAL) to regulate metabolism in temozolomide-treated C6 glioma cells. The gene discussed is NOS2; the disease is central nervous system cancer.